GlassScriptPhysician profile
Ira A Shivitz
NPI 1881690766
$9,036.53
in general payments reported to CMS, 2019-2025
28 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $971 · 2021: $1,223 · 2022: $1,553 · 2023: $803 · 2024: $1,476 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,279.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,350.30 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Allergan, INC. | $1,095.28 | 2020-2022 | |
| Biotissue Holdings INC. | $923.31 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $711.42 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $700.91 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $517.32 | 2019-2022 | |
| Oyster Point Pharma, INC. | $429.40 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Glaukos Corporation | $376.00 | 2023-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Harrow Eye, LLC | $350.42 | 2023-2025 | Vevye, Iheezo |
| Eyevance Pharmaceuticals LLC | $340.48 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $327.79 | 2019-2025 | Cequa |
| Alcon Vision LLC | $321.68 | 2019-2025 | Rocklatan, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $303.80 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $222.66 | 2023-2025 | Iyuzeh |
| Dompe US, INC. | $192.73 | 2019-2025 | Oxervate |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $162.21 | 2019 | |
| Rxsight INC | $152.19 | 2022 | |
| Kala Pharmaceuticals, INC. | $119.87 | 2019-2021 | |
| Akorn, INC. | $70.23 | 2020 | |
| Mallinckrodt Enterprises LLC | $63.25 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $60.72 | 2022-2024 | Tecnis Iol, Catalys System |
| Aerie Pharmaceuticals, INC. | $59.20 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $50.08 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $43.02 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $25.09 | 2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $23.73 | 2024 | |
| New World Medical,INC. | $23.09 | 2024 | Streamline, Kahook Dual Blade, Clearpath |
| Tearlab Corp | $20.35 | 2024 | Scoutpro Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Shivitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.